Novo Nordisk CEO anticipates pills could capture 50% of weight-loss market by 2030

by@Reuters

Summary

Novo Nordisk's CEO, Mike Doustdar, announced that weight-loss pills could capture up to 50% of the global obesity drug market by 2030, as the company prepares for a significant shift away from weekly injections. This statement came during Novo's Capital Markets Day in London, where Doustdar highlighted that the company's five oral treatments in development position it advantageously, especially as major competitors are still focused on injectables, which outnumber the oral candidates in their pipelines. Since the launch of its Wegovy weight-loss pill in 2021, which generated nearly 5.5 billion Danish crowns in first-half sales, Novo had reclaimed a strong foothold in the market, despite recent stock declines attributed to competition from Eli Lilly.

Tokens

$NOVO$LLY

Analysis

Wegovy: Wegovy is Novo Nordisk's leading weight-loss medication, now available in both injectable and oral formulations. The oral version has contributed to growth in US prescriptions for the company. It forms a key part of Novo's response to evolving patient preferences and competitive pressures. Eli Lilly: Eli Lilly is a US-based pharmaceutical company and direct competitor to Novo Nordisk in the obesity treatment space. It maintains a strong emphasis on injectable formulations across its development efforts. This focus contrasts with Novo's push into oral options, potentially shaping longer-term market dynamics. zenagamtide: zenagamtide is a next-generation dual-acting oral tablet under development in Novo Nordisk's obesity pipeline. It joins other oral candidates such as an amylin analogue and a small-molecule drug. The asset supports the company's broader push to expand its range of pill-based treatments. Novo Nordisk: Novo Nordisk is a Danish pharmaceutical company focused on treatments for diabetes and obesity. It recently launched an oral version of its weight-loss medication and is advancing several additional pill candidates in its pipeline. The company is actively preparing for greater competition and market shifts toward oral therapies as highlighted during its recent Capital Markets Day. Mike Doustdar: Mike Doustdar serves as chief executive officer of Novo Nordisk. He recently addressed the company's strategy for oral obesity treatments following its Capital Markets Day in London. His remarks emphasized preparation for scenarios where pills play a much larger role alongside injectables. Competitive Focus: Major rivals continue to prioritize injectable candidates, with far more such assets in development than oral ones. Pipeline Strategy: Novo Nordisk is advancing five oral obesity treatments to diversify beyond its initial pill launch. Market Preparation: The company is positioning itself for potential shifts in patient preferences toward convenient oral options in obesity care.

Categories

macro
View Original Tweet